A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants

被引:33
|
作者
Khan, David D. [1 ]
Lagerback, Pernilla [2 ]
Cao, Sha [3 ]
Lustig, Ulrika [3 ]
Nielsen, Elisabet I. [1 ]
Cars, Otto [2 ]
Hughes, Diarmaid [3 ]
Andersson, Dan I. [3 ]
Friberg, Lena E. [1 ]
机构
[1] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
[2] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[3] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden
关键词
PHARMACOKINETIC-PHARMACODYNAMIC MODEL; ANTIMICROBIAL RESISTANCE; IN-VITRO; CIPROFLOXACIN; AGENTS; COLISTIN; PHARMACOMETRICS; STABILITY; EVOLUTION; RESPONSES;
D O I
10.1093/jac/dkv233
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: In silico pharmacokinetic/pharmacodynamic (PK/PD) models can be developed based on data from in vitro time-kill experiments and can provide valuable information to guide dosing of antibiotics. The aim was to develop a mechanism-based in silico model that can describe in vitro time-kill experiments of Escherichia coli MG1655 WT and six isogenic mutants exposed to ciprofloxacin and to identify relationships that may be used to simplify future characterizations in a similar setting. Methods: In this study, we developed a mechanism-based PK/PD model describing killing kinetics for E. coli following exposure to ciprofloxacin. WT and six well-characterized mutants, with one to four clinically relevant resistance mutations each, were exposed to a wide range of static ciprofloxacin concentrations. Results: The developed model includes susceptible growing bacteria, less susceptible (pre-existing resistant) growing bacteria, non-susceptible non-growing bacteria and non-colony-forming non-growing bacteria. The non-colony-forming state was likely due to formation of filaments and was needed to describe data close to the MIC. A common model structure with different potency for bacterial killing (EC50) for each strain successfully characterized the time-kill curves for both WT and the six E. coli mutants. Conclusions: The model-derived mutant-specific EC50 estimates were highly correlated (r(2) = 0.99) with the experimentally determined MICs, implying that the in vitro time-kill profile of a mutant strain is reasonably well predictable by the MIC alone based on the model.
引用
收藏
页码:3051 / 3060
页数:10
相关论文
共 28 条
  • [1] Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
    Sukumaran, Siddharth
    Gadkar, Kapil
    Zhang, Crystal
    Bhakta, Sunil
    Liu, Luna
    Xu, Keyang
    Raab, Helga
    Yu, Shang-Fan
    Mai, Elaine
    Fourie-O'Donohue, Aimee
    Kozak, Katherine R.
    Ramanujan, Saroja
    Junutula, Jagath R.
    Lin, Kedan
    PHARMACEUTICAL RESEARCH, 2015, 32 (06) : 1884 - 1893
  • [2] Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
    Siddharth Sukumaran
    Kapil Gadkar
    Crystal Zhang
    Sunil Bhakta
    Luna Liu
    Keyang Xu
    Helga Raab
    Shang-Fan Yu
    Elaine Mai
    Aimee Fourie-O’Donohue
    Katherine R. Kozak
    Saroja Ramanujan
    Jagath R. Junutula
    Kedan Lin
    Pharmaceutical Research, 2015, 32 : 1884 - 1893
  • [3] Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment
    Harrold, John M.
    Abraham, Anson K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 (02) : 141 - 151
  • [4] Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment
    John M. Harrold
    Anson K. Abraham
    Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41 : 141 - 151
  • [5] Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
    Ng, Chee M.
    Patnaik, A.
    Beeram, M.
    Lin, C. C.
    Takimoto, C. H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (05) : 985 - 994
  • [6] Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model
    Lin, Yu-Wei
    Zhou, Qi Tony
    Han, Mei-Ling
    Onufrak, Nikolas J.
    Chen, Ke
    Wang, Jiping
    Forrest, Alan
    Chan, Hak-Kim
    Li, Jian
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (03)
  • [7] Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
    Chee M. Ng
    A. Patnaik
    M. Beeram
    C. C. Lin
    C. H. Takimoto
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 985 - 994
  • [8] Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans
    Abraham, Anson K.
    Mager, Donald E.
    Gao, Xiang
    Li, Mei
    Healy, David R.
    Maurer, Tristan S.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 330 (01): : 169 - 178
  • [9] Novel Mechanism-based Population Pharmacokinetic/Pharmacodynamic Model of Blood Pressure and the Antihypertensive Activity of Fimasartan
    Bulitta, Juergen
    Paik, Soo-Heui
    Shin, Soyoung
    Landersdorfer, Cornelia
    Kim, Tae Hwan
    Kim, Min Gi
    Jeong, Seok Won
    Yadav, Rajbharan
    Shin, Beom Soo
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S100 - S100
  • [10] Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize tumor killing effect of an anti-VISTA monoclonal antibody in tumor bearing mice
    Jiang, Xiling
    Leu, Jocelyn
    Singh, Indrajeet
    Snyder, Linda A.
    Wang, Weirong
    CANCER RESEARCH, 2016, 76